Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 18, 2016HaematologicaOpen Access

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

View Full Paper
Ask AI
Bookmark
Share

Authors

ANAziz NazhaRKRami S. KomrokjiGGG. Garcia-Manero

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nazha et al. (2016) studied this question.

synapsesocial.com/papers/6a851fdc0743ff3319d979bfhttps://doi.org/10.3324/haematol.2015.140962
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes2007 · 1,039 citations
  2. 2The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes2009 · 4,458 citations
  3. 3Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy2010 · 280 citations
  4. 4Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B2002 · 1,830 citations
  5. 5Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System2008 · 486 citations